Professor Saye Khoo MB,BS, MRCP, DTM&H, FRCP, MD, Diploma in Epidemiology

Professor(Clin, Hcc) Pharmacology & Therapeutics

    Publications

    Selected Publications

    1. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study (Journal article - 2022)
    2. An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2 (Journal article - 2022)
    3. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study (Journal article - 2021)
    4. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study) (Journal article - 2019)
    5. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial (Journal article - 2016)
    6. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries (Journal article - 2014)
    7. Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. (Journal article - 1999)
    8. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial (Journal article - 2022)
    9. Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial (Journal article - 2022)